-
Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism
… : Transgenic pre-clinical models are instrumental to investigate mutation-induced abnormalities at the … disease and (ii) an identification of a possible target for early diagnosis and disease modifying therapies. … pre-clinical models to provide a set of observables common to transgenic pre-clinical models and humans. …
-
Developing Small Molecules to Enhance Autophagy and Clear Alpha-synuclein Aggregates as a Treatment for Parkinson’s Disease
… cells dispose of damaged or improperly functioning cell components. Recent evidence points at defects in autophagy … thus has potential as a treatment to modify PD progression. For this reason, we are developing small molecules that can enhance autophagy. Such novel compounds should reduce alpha-synuclein accumulation, …
-
Elucidating the Mechanism of Action of J3, A Neuroprotective Small Molecule Candidate to Treat Parkinson's Disease
… We have identified a small molecule, designated J3, which shows promising neuroprotection in an acute animal model of Parkinson’s disease. To reach our ultimate goal of developing a disease-modifying … effort, we propose to identify the cellular processes and components that are altered by J3 and use this information …
-
New Educational Program Partners in Parkinson’s to Kick Off in New York City on May 18
April 7, 2014
… The Michael J. Fox Foundation and AbbVie have partnered to create Partners in Parkinson’s , a strategic health … new educational tools and resources for the Parkinson’s community to help optimize care at every stage of disease. … events will offer new insights on topics including: How to make the most of your relationship with your doctor, …
-
Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway
… USP30 is an enzyme which acts in the opposite way to Parkin (PRKN), a gene linked to young-onset Parkinson’s … clinical trials. Next Steps for Development: If outcomes are positive, and our USP30 inhibitor also passes … into human trials, confirming that enough USP30 inhibitor gets into the human brain, before progression to human …
-
Developing Disease-Modifying Therapies to Treat Parkinsons’s Disease by Enhancing the Clearance of Alpha Synuclein
… Objective/Rationale: This proposal seeks to develop a novel therapy that can slow the progression of Parkinson’s disease (PD) by optimizing chemical compounds that can decrease levels of alpha synuclein in the … the project is to develop a chemical compound that can be tested in the clinic for its ability to slow the clinical …